Skip to main content

Regeneron for Hemophilia B

Regeneron for Hemophilia B

Contact

If you are interested in participating in the study or want to learn more, please get in touch. Contact us
This study is no longer recruiting.

Description

This research study is seeking participants who have hemophilia B and need regular preventive treatment with factor IX protein (FIX) replacement therapy to prevent and also control bleeding events. To join the study , you must be male as assigned at birth, and between the ages of 16 and 65 years at the time of signing the informed consent form. The purpose of this study is to gather at least 6 months of information on bleeding events for each individual participant while they continue to use their usual FIX replacement therapy. There is no experimental drug or treatment being tested in this study. The study is informational, and part of a larger program to understand and treat hemophilia B with a potential experimental new therapy in the future. After participants complete this research study, should they be interested and eligible, they may be offered the opportunity to take part in a future study with this new therapy. There is no obligation to agree to taking part in this future study.

Eligibility and criteria


IRB Number:
23-021189
Eligible age range:
16 years - 65 years
Clinical trial phase:
N/A
Official title:
A Prospective Study To Evaluate Disease Characteristics In Hemophilia B Participants Receiving Prophylaxis With Standard Of Care Fix Replacement Therapy
Smiling CHOP patient holding shopping bag

We need families like you

Your time and participation make a difference in supporting the work of the Research Institute and children in our community. Learn more about opportunities to participate in our research.

Jump back to top